Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) closed the day trading at $687.80 up 0.91% from the previous closing price of $681.58. In other words, the price has increased by $0.91 from its previous closing price. On the day, 1.15 million shares were traded. REGN stock price reached its highest trading level at $692.93 during the session, while it also had its lowest trading level at $681.52.
Ratios:
For a better understanding of REGN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.97. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 5.28. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 16, 2025, Downgraded its rating to Neutral and sets its target price to $738 from $1130 previously.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $1150.Wolfe Research initiated its Outperform rating on November 15, 2024, with a $1150 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 01 ’24 when McCourt Marion sold 1,000 shares for $844.61 per share. The transaction valued at 844,610 led to the insider holds 12,931 shares of the business.
MARION E MCCOURT bought 1,000 shares of REGN for $844,610 on Nov 01 ’24. On Oct 01 ’24, another insider, RYAN ARTHUR F, who serves as the Director of the company, sold 100 shares for $1048.78 each. As a result, the insider received 104,878 and left with 17,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 75582341120 and an Enterprise Value of 66907578368. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.02, and their Forward P/E ratio for the next fiscal year is 15.36. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.46 while its Price-to-Book (P/B) ratio in mrq is 2.58. Its current Enterprise Value per Revenue stands at 4.832 whereas that against EBITDA is 14.551.
Stock Price History:
Over the past 52 weeks, REGN has reached a high of $1211.20, while it has fallen to a 52-week low of $666.25. The 50-Day Moving Average of the stock is -7.48%, while the 200-Day Moving Average is calculated to be -28.21%.
Shares Statistics:
Over the past 3-months, REGN traded about 866.06K shares per day on average, while over the past 10 days, REGN traded about 909650 shares per day. A total of 108.30M shares are outstanding, with a floating share count of 105.92M. Insiders hold about 3.61% of the company’s shares, while institutions hold 85.59% stake in the company. Shares short for REGN as of 1735603200 were 2095552 with a Short Ratio of 2.42, compared to 1732838400 on 1799097. Therefore, it implies a Short% of Shares Outstanding of 2095552 and a Short% of Float of 2.01.
